Abstract
Glutathione (GSH) has several roles in a cell, such as a reactive oxygen species (ROS) scavenger, an intervenient in xenobiotics metabolism and a reservoir of cysteine. All of these activities are important in the maintenance of normal cells homeostasis but can also constitute an advantage for cancer cells, allowing disease progression and resistance to therapy. Ovarian cancer is the major cause of death from gynaecologic disease and the second most common gynaecologic malignancy worldwide. In over 50 years, the overall survival of patients diagnosed with epithelial ovarian cancer has not changed, regardless of the efforts concerning early detection, radical surgery and new therapeutic approaches. Late diagnosis and resistance to therapy are the main causes of this outcome, and GSH is profoundly associated with chemoresistance to platinum salts, which, together with taxane-based chemotherapy and surgery, are the main therapy strategies in ovarian cancer treatment. Herein, we present some insights into the role of GSH in the poor prognosis of ovarian cancer, and also point out how some strategies underlying the dependence of ovarian cancer cells on GSH can be further used to improve the effectiveness of therapy.
| Original language | English |
|---|---|
| Article number | 1882 |
| Journal | International Journal Of Molecular Sciences |
| Volume | 19 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 26 Jun 2018 |
Fingerprint
Keywords
- Cancer metabolism
- Chemoresistance
- Cysteine
- Glutathione
- Ovarian cancer
- Platinum based drugs
Cite this
}
Glutathione in Ovarian Cancer : A Double-Edged Sword. / Nunes, Sofia C.; Serpa, Jacinta.
In: International Journal Of Molecular Sciences, Vol. 19, No. 7, 1882, 26.06.2018.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Glutathione in Ovarian Cancer
T2 - A Double-Edged Sword
AU - Nunes, Sofia C.
AU - Serpa, Jacinta
N1 - info:eu-repo/grantAgreement/FCT/PD/PD%2FBD%2F105893%2F2014/PT# This research group is supported by Fundação para a Ciência e Tecnologia (FCT) (PhD ProRegeM program, PD/BD/105893/2014, FCT fellowship, PD/BD/105768/2014). iNOVA4Health—UID/Multi/04462/2013, a program financially supported by Fundação para a Ciência e Tecnologia / Ministério da Educação e Ciência, through national funds and co-funded by FEDER under the PT2020 Partnership Agreement is acknowledged.
PY - 2018/6/26
Y1 - 2018/6/26
N2 - Glutathione (GSH) has several roles in a cell, such as a reactive oxygen species (ROS) scavenger, an intervenient in xenobiotics metabolism and a reservoir of cysteine. All of these activities are important in the maintenance of normal cells homeostasis but can also constitute an advantage for cancer cells, allowing disease progression and resistance to therapy. Ovarian cancer is the major cause of death from gynaecologic disease and the second most common gynaecologic malignancy worldwide. In over 50 years, the overall survival of patients diagnosed with epithelial ovarian cancer has not changed, regardless of the efforts concerning early detection, radical surgery and new therapeutic approaches. Late diagnosis and resistance to therapy are the main causes of this outcome, and GSH is profoundly associated with chemoresistance to platinum salts, which, together with taxane-based chemotherapy and surgery, are the main therapy strategies in ovarian cancer treatment. Herein, we present some insights into the role of GSH in the poor prognosis of ovarian cancer, and also point out how some strategies underlying the dependence of ovarian cancer cells on GSH can be further used to improve the effectiveness of therapy.
AB - Glutathione (GSH) has several roles in a cell, such as a reactive oxygen species (ROS) scavenger, an intervenient in xenobiotics metabolism and a reservoir of cysteine. All of these activities are important in the maintenance of normal cells homeostasis but can also constitute an advantage for cancer cells, allowing disease progression and resistance to therapy. Ovarian cancer is the major cause of death from gynaecologic disease and the second most common gynaecologic malignancy worldwide. In over 50 years, the overall survival of patients diagnosed with epithelial ovarian cancer has not changed, regardless of the efforts concerning early detection, radical surgery and new therapeutic approaches. Late diagnosis and resistance to therapy are the main causes of this outcome, and GSH is profoundly associated with chemoresistance to platinum salts, which, together with taxane-based chemotherapy and surgery, are the main therapy strategies in ovarian cancer treatment. Herein, we present some insights into the role of GSH in the poor prognosis of ovarian cancer, and also point out how some strategies underlying the dependence of ovarian cancer cells on GSH can be further used to improve the effectiveness of therapy.
KW - Cancer metabolism
KW - Chemoresistance
KW - Cysteine
KW - Glutathione
KW - Ovarian cancer
KW - Platinum based drugs
U2 - 10.3390/ijms19071882
DO - 10.3390/ijms19071882
M3 - Review article
VL - 19
JO - International Journal Of Molecular Sciences
JF - International Journal Of Molecular Sciences
SN - 1422-0067
IS - 7
M1 - 1882
ER -